


PHARMACEUTICAL 2023

Theravance Biopharma Inc. Rank 1 of 446









RealRate

PHARMACEUTICAL 2023





The relative strengths and weaknesses of Theravance Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 402% points. The greatest weakness of Theravance Biopharma Inc. is the variable Other Assets, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 587%, being 544% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	353,464
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,715
Liabilities, Non-Current	0
Other Assets	242,061
Other Compr. Net Income	-15
Other Expenses	19,216
Other Liabilities	0
Other Net Income	970,467
Other Revenues	51,346
Property and Equipment	11,875
Research and Development	63,392
Selling, General and Administrative Expense	67,073

Output Variable	Value in 1000 USD
Assets	607,400
Liabilities	28,715
Expenses	149,681
Revenues	51,346
Stockholders Equity	578,685
Net Income	872,132
Comprehensive Net Income	872,124
Economic Capital Ratio	587%

